Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 in Younger Patients < 60 Years Old With Secondary Acute Myeloid Leukemia
NCT04269213Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jul 2021
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytarabine in acute myeloid leukemia (AML), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Complete Response Rate at 45 days. Started Jul 2021; status: completed.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04269213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04269213.